Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 867648 | ISIN: US5928351023 | Ticker-Symbol: MXF
Berlin
14.01.25
21:48 Uhr
13,000 Euro
-0,100
-0,76 %
1-Jahres-Chart
MEXICO FUND INC Chart 1 Jahr
5-Tage-Chart
MEXICO FUND INC 5-Tage-Chart
PR Newswire
176 Leser
Artikel bewerten:
(1)

The Mexico Fund, Inc. Issues Its 2024 Semi-annual Report

Finanznachrichten News

COLUMBIA, Md., June 25, 2024 /PRNewswire/ -- The Mexico Fund, Inc. (NYSE: MXF), today issued its fiscal 2024 Semi-Annual Report for the period ended April 30, 2024.

A full version of the report is available at the company's website - www.themexicofund.com

Semi-Annual Report 2024 Highlights

During the first half of fiscal year 2024, the Fund's NAV per share registered a total return of 21.62%, compared with a return of 21.58% registered by its benchmark, the Morgan Stanley Capital International ("MSCI") Mexico Index, while the Fund's market price registered a total return of 22.06%. The Fund's NAV per share has outperformed its benchmark during the one-, five-, ten- and fifteen-year periods ended on April 30, 2024, as shown in the table below:



Annualized % Return in USD


1-year

3-years

5-years

10-years

15-years

MXF Market Price

13.20

12.67

9.36

1.85

8.89

MXF NAV

11.38

14.93

10.91

3.35

9.00

MSCI Mexico Index

9.55

15.06

9.78

2.56

7.16








As of April 30, 2024, the Fund's market price and NAV per share were $17.99 and $22.62, respectively, reflecting a discount of 20.47%, compared with a discount of 20.40% at the end of fiscal year 2023.

The Fund's Expense Limitation Agreement was renewed for fiscal year 2024, with a cap on the ordinary expense ratio, which excludes the performance component of the Investment Advisory fee, of 1.40%, so long as Fund net assets remain greater than $260 million. The Fund's ordinary expense ratio during the first half of fiscal year 2024 was 1.34%, below the limit of 1.40%.

The Board of Directors of the Fund has ratified the continuation of the Fund's quarterly distributions under its MDP during 2024. As a result, it declared a distribution of $0.22 per share to be paid on July 25, 2024, to stockholders of record as of July 17, 2024.

About The Mexico Fund, Inc.

The Mexico Fund, Inc. is a non-diversified closed-end management investment company with the investment objective of long-term capital appreciation through investments in securities, primarily equity, listed on the Mexican Stock Exchange. The Fund provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

This release may contain certain forward-looking statements regarding future circumstances. These forward-looking statements are based upon the Fund's current expectations and assumptions and are subject to various risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements including, in particular, the risks and uncertainties described in the Fund's filings with the Securities and Exchange Commission. Actual results, events, and performance may differ. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Fund undertakes no obligation to release publicly any revisions to these forward looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The inclusion of any statement in this release does not constitute an admission by The Mexico Fund or any other person that the events or circumstances described in such statement are material.

CONTACT:
Tofi Dayan
+5255-9138-3350
Email: [email protected]

SOURCE The Mexico Fund, Inc.

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.